Home > Boards > US Listed > Biotechs > RedHill Biopharma Ltd. (RDHL)

Revenue is stagnating..

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
midastouch017 Member Profile
 
Followed By 115
Posts 25,016
Boards Moderated 9
Alias Born 02/07/04
160x600 placeholder
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 1/15/2021 11:20:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 2:29:29 PM
RedHill Biopharma Announces Closing of $25 Million Bought Deal Offering PR Newswire (US) - 1/14/2021 2:13:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/14/2021 9:22:31 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/13/2021 5:10:30 PM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 1/12/2021 8:57:39 AM
RedHill Biopharma Increases Previously Announced Bought Deal to $25 Million PR Newswire (US) - 1/12/2021 8:51:00 AM
Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp) Edgar (US Regulatory) - 1/11/2021 4:52:52 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/11/2021 4:48:14 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/11/2021 4:45:32 PM
RedHill Biopharma Announces $10 Million Bought Deal Offering PR Newswire (US) - 1/11/2021 4:35:00 PM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/11/2021 7:00:29 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (Canada) - 1/11/2021 7:00:00 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (US) - 1/11/2021 7:00:00 AM
RedHill's Partner Cosmo Pharmaceuticals Successfully Completes Phase 2 Study of Rifamycin SV-MMX 600mg in IBS-D PR Newswire (US) - 1/11/2021 7:00:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 1/6/2021 7:00:43 AM
RedHill Biopharma's RHB-204 Granted FDA Fast Track Designation for NTM Disease PR Newswire (US) - 1/6/2021 7:00:00 AM
RedHill Releases ‘Positive’ Results From Early Covid-19 Trial With Opaganib; Shares Drop 5.6% TipRanks - 1/1/2021 3:05:29 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/31/2020 9:30:59 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (US) - 12/31/2020 9:30:00 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (US) - 12/31/2020 9:30:00 AM
RedHill Biopharma Announces Positive Top-Line Safety and Efficacy Data from Phase 2 COVID-19 Study of Opaganib PR Newswire (Canada) - 12/31/2020 9:30:00 AM
Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) Edgar (US Regulatory) - 12/22/2020 7:00:59 AM
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire (US) - 12/22/2020 7:00:00 AM
RedHill's Phase 2/3 COVID-19 Study of Opaganib Passes Second DSMB with Unanimous Recommendation to Continue PR Newswire (Canada) - 12/22/2020 7:00:00 AM
midastouch017   Thursday, 07/23/20 07:42:56 AM
Re: vautee2910 post# 1503
Post # of 2752 
Quote:
Revenue is stagnating..



This is definitely not the case now!

smile

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences